At the upcoming Pharmaceutical Benefits Advisory Committee (PBAC) meeting in July, there will be two submissions made relating to drugs that are used to treat myeloma, namely daratumumab and carfilzom...
May
2020
23
Apr
2020
02
Lenalidomide (Revlimid®) maintenance post autologous stem cell transplant We are delighted to announce that as of 1 April 2020 the pharmaceutical benefits scheme (PBS) have listed lenalidomide (Revlim...
Mar
2020
13
Our Information and Support Groups are informal gatherings for people living with myeloma, their family and friends. These meetings provide a safe space to meet other members of the myeloma community ...
Dec
2019
20
Earlier this month, a team from Myeloma Australia visited Orlando, Florida in the USA for the annual American Society of Hematology (ASH) conference as invited guests of the International Myeloma Foun...
Sep
2019
19
A couple of weeks ago we sent out a special advocacy edition of the Muster to inform you of the latest submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for the upcoming November PB...
Sep
2019
13
Cytogenetics is the study of chromosomes within a cell. Most commonly done at diagnosis, cytogenetic testing identifies the genetic mutations which characterise a person’s myeloma. This information he...
Feb
2019
01
A team from Myeloma Australia visited San Diego USA in December 2018 as invited guests of the International Myeloma Foundation (IMF). This gave us the opportunity to attend the world’s largest haemato...